NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · CYT · USD
Stock price, dividends, earnings
Quote as of Mar 15, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Cyteir Therapeutics, Inc.’s forward annual dividend is $0.52 per share, paid quarterly. The forward yield is 17.22% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cyteir Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| -$0.40-2.56% vs estimate |
| $0.00 |
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$2.09-$0.01 (-0.48%)
HilleVax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.69% below the high.
$1.88$0.00 (0.0%)
Jounce Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.99% below the high.
$2.05-$0.05 (-2.38%)
Aadi Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.22% below the high.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
